Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.

  title={Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.},
  author={Federico Pea and Pierluigi Viale and Piergiorgio Cojutti and Barbara Del Pin and Eleonora Zamparini and Mario Furlanut},
  journal={The Journal of antimicrobial chemotherapy},
  volume={67 8},
OBJECTIVES Prolonged treatment with linezolid may cause toxicity. The purpose of this study was to define pharmacodynamic thresholds for improving safety outcomes of linezolid. METHODS We performed a retrospective study of patients who had trough (C(min)) and peak (C(max)) plasma levels measured during prolonged linezolid treatment. Dosage adjustments were performed when C(min) ≥10 mg/L and/or AUC₂₄ ≥400 mg/L · h. Patients were divided into two subgroups according to the absence or presence… 

Figures and Tables from this paper

Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?—Experience from a prospective observational study

The results suggest that the pharmacodynamic range of linezolid Cmin can be defined as 2–8 mg/L for the Chinese population, and the application of TDM might be especially valuable in optimizinglinezolid exposure in the majority of patients to avoid therapeutic failure and/or dose-dependent adverse reactions.

Variable Linezolid Exposure in Intensive Care Unit Patients—Possible Role of Drug–Drug Interactions

Drug exposure after standard doses of linezolid is highly variable and difficult to predict in ICU patients, and therapeutic drug monitoring seems advisable; protein binding appears to be stable and irrelevant.

Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients

Empirical dose reduction to 300 mg every 12 h after administration of the initial fixed dose for 2 days and C min -based TDM may improve safety outcomes while maintaining appropriate efficacy among patients with renal impairment.

Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia

It is important to maintain the linezolid level within the therapeutic range at the first therapeutic drug monitoring to prevent thrombocytopenia.

Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study

Permanent discontinuation of linezolid was common, but lineZolid-containing therapy was associated with average improvement in toxicity measures, and linezolic trough concentration of 2.5 mg/L should be evaluated as a target for therapeutic drug monitoring.

Decreased Linezolid Serum Concentrations in Three Critically Ill Patients: Clinical Case Studies of a Potential Drug Interaction between Linezolid and Rifampicin

It is strongly recommended that linezolid serum concentrations be monitored in patients with rifampicin co-administration or rifampsicin pretreatment in order to avoid treatment failure.

Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients

Renal function plays a significant role in linezolid PKs for critically ill patients, and a dose of 600 mg every 24 h was recommended for patients with CrCL <60 ml/min to minimizelinezolid-induced myelosuppression.

Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients.




Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis

The study suggests that the application of TDM might be especially worthwhile in about 30% of cases with the intent of avoiding either the risk of dose-dependent toxicity or that of treatment failure.

Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid

Pyridoxine did not prevent linezolid-related hematological adverse events, and the coadministration of rifampin was associated with a lower risk of thrombocytopenia.

Pharmacokinetics of linezolid in septic patients with and without extended dialysis

The results suggest that linezolid pharmacokinetics in critically ill patients with ARF undergoing ED is not comparable to that in healthy subjects and patients without ARF, and the best method of managing lineZolid dosage in such a complex group of patients, whose physiology can vary daily, would be to use therapeutic drug monitoring.

Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients.

Preliminary data suggest a potential role for linezolid in the treatment of cholangitis due to VRE in LTx patients, and further confirmatory data assessing also the AUC/MIC ratio of lineZolid in bile are needed.

Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?

Linezolid/rifampicin combination therapy was associated with a significantly reduced incidence of anaemia among patients with bone and joint infections, but it did not have an effect on thrombocytopenia and peripheral neuropathy rates.

Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy

  • Y. TakahashiY. Takesue M. Uchino
  • Medicine, Biology
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • 2011
A retrospective study of patients treated with linezolid 600 mg q12h, by the oral or parenteral route, between July 2007 and June 2009, found several factors influenced the occurrence of lineZolid-induced thrombocytopenia.

Clarithromycin Significantly Increases Linezolid Serum Concentrations

A 42-year-old male patient was admitted at our hospital for treatment of smear-positive pulmonary tuberculosis (TB). Drug sensitivity testing revealed extensively drug-resistant TB, and the isolate

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism

Modeling of these data suggested that rifampin inducible drug metabolizing enzymes, such as cytochrome P4503A, have a very minor contribution to linezolid clearance, which increases when rifampsin is coadministered.